News

October 22, 2019

Imfinzi Lessens Cancer Spread, Explaining Extended Survival in NSCLC Patients, Phase 3 Data Show

News

AstraZeneca‘s Imfinzi (durvalumab) decreases the spread of cancer to other parts of the body, explaining the enhanced survival in patients with stage 3 inoperable non-small-cell lung cancer (NSCLC), according to ... Read more

October 18, 2019

First Patients Dosed in Phase 1/2 Trial Testing Galinpepimut-S, Keytruda Combo in Advanced Cancers

News

A Phase 1/2 clinical trial assessing the cancer vaccine galinpepimut-S in combination with Keytruda (pembrolizumab) as a treatment for WT-1-positive advanced cancers has started dosing patients, Sellas Life Sciences ... Read more

October 16, 2019

Opdivo Superior to Chemotherapy in Patients with Advanced Esophageal Cancer, Trial Shows

News

Bristol-Myers Squibb‘s Opdivo (nivolumab) is superior to chemotherapy for treating patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) that cannot be removed surgically, and who are resistant ... Read more

October 15, 2019October 16, 2019

Phio Partners with German Research Center to Develop New Generation of Cancer Immunotherapies

News

Phio Pharmaceuticals and researchers with Helmholtz Zentrum München — the German Research Center for Environmental Health (HMGU) — are working together to develop new approaches to boost the immune system in ... Read more

October 9, 2019October 9, 2019

Keytruda Approved in China as First-Line Lung Cancer Treatment

News

The Chinese National Medical Products Administration (NMPA) has approved Keytruda (pembrolizumab) as a first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC), Merck (known as MSD outside the U.S. and Canada) ... Read more

October 8, 2019

Opdivo-Yervoy Combo Prolongs Survival in Patients with Advanced NSCLC, Phase 3 Study Shows

News

A combination of Opdivo (nivolumab) and low-dose Yervoy (ipilimumab) induces significant survival benefits in people with advanced non-small cell lung cancer (NSCLC), compared to chemotherapy alone, data from a ... Read more

October 4, 2019October 8, 2019

Lenvima-Keytruda Combo Maintains Positive Results in Advanced Endometrial Cancer

News

Combination therapy with Lenvima (lenvatinib) and Keytruda (pembrolizumab) continues to show promising antitumor results in patients with advanced endometrial cancer, the most common cancer of the uterus, according to ... Read more

October 2, 2019

Tecentriq Prolongs Survival of Patients with Advanced Lung Cancer Beyond Chemo, Phase 3 Trial Shows

News

Tecentriq (atezolizumab) prolongs the lives of patients with advanced non-squamous and squamous non-small cell lung cancer (NSCLC) when administered as a first-line therapy, compared to chemotherapy, according to the ... Read more

October 1, 2019

Opdivo Boosts Long-Term Survival of Advanced Lung Cancer Patients, Phase 3 Trials Show

News

Opdivo (nivolumab) continues to increase the long-term overall survival of patients with advanced non-small cell lung cancer (NSCLC) compared to the chemotherapy Taxotere (docetaxel), according to pooled data from ... Read more

September 27, 2019

Maeton’s OT101 Gets Rare Pediatric Disease Designation for Childhood Brain Tumor

News

The U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation to Mateon‘s OT101 as a therapy for diffuse intrinsic pontine glioma (DIPG), a difficult-to-treat brain tumor that ... Read more

Pin It on Pinterest